160 related articles for article (PubMed ID: 34490741)
1. Glucose-dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: A randomized, double-blind, placebo-controlled, crossover clinical trial.
Heimburger SMN; Nielsen CN; Calanna S; Holst JJ; Vilsbøll T; Knop FK; Christensen MB
Diabetes Obes Metab; 2022 Jan; 24(1):142-147. PubMed ID: 34490741
[TBL] [Abstract][Full Text] [Related]
2. The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial.
Heimbürger SMN; Hoe B; Nielsen CN; Bergmann NC; Hartmann B; Holst JJ; Vilsbøll T; Dejgaard TF; Christensen MB; Knop FK
Diabetologia; 2021 Nov; 64(11):2425-2431. PubMed ID: 34405256
[TBL] [Abstract][Full Text] [Related]
3. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals.
Gasbjerg LS; Helsted MM; Hartmann B; Sparre-Ulrich AH; Veedfald S; Stensen S; Lanng AR; Bergmann NC; Christensen MB; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 32077470
[TBL] [Abstract][Full Text] [Related]
4. Effects of endogenous GIP in patients with type 2 diabetes.
Stensen S; Gasbjerg LS; Krogh LL; Skov-Jeppesen K; Sparre-Ulrich AH; Jensen MH; Dela F; Hartmann B; Vilsbøll T; Holst JJ; Rosenkilde MM; Christensen MB; Knop FK
Eur J Endocrinol; 2021 May; 185(1):33-45. PubMed ID: 33886495
[TBL] [Abstract][Full Text] [Related]
5. GIP(3-30)NH
Gasbjerg LS; Christensen MB; Hartmann B; Lanng AR; Sparre-Ulrich AH; Gabe MBN; Dela F; Vilsbøll T; Holst JJ; Rosenkilde MM; Knop FK
Diabetologia; 2018 Feb; 61(2):413-423. PubMed ID: 28948296
[TBL] [Abstract][Full Text] [Related]
6. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans.
Christensen MB
Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034187
[TBL] [Abstract][Full Text] [Related]
7. Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes.
Christensen M; Calanna S; Sparre-Ulrich AH; Kristensen PL; Rosenkilde MM; Faber J; Purrello F; van Hall G; Holst JJ; Vilsbøll T; Knop FK
Diabetes; 2015 Jan; 64(1):72-8. PubMed ID: 25053587
[TBL] [Abstract][Full Text] [Related]
8. Endogenous Glucose-Dependent Insulinotropic Polypeptide Contributes to Sitagliptin-Mediated Improvement in β-Cell Function in Patients With Type 2 Diabetes.
Stensen S; Gasbjerg LS; Rosenkilde MM; Vilsbøll T; Holst JJ; Hartmann B; Christensen MB; Knop FK
Diabetes; 2022 Oct; 71(10):2209-2221. PubMed ID: 35796651
[TBL] [Abstract][Full Text] [Related]
9. Effects of glucose-dependent insulinotropic polypeptide on gastric emptying, glycaemia and insulinaemia during critical illness: a prospective, double blind, randomised, crossover study.
Kar P; Cousins CE; Annink CE; Jones KL; Chapman MJ; Meier JJ; Nauck MA; Horowitz M; Deane AM
Crit Care; 2015 Jan; 19(1):20. PubMed ID: 25613747
[TBL] [Abstract][Full Text] [Related]
10. Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes.
Christensen MB; Calanna S; Holst JJ; Vilsbøll T; Knop FK
J Clin Endocrinol Metab; 2014 Mar; 99(3):E418-26. PubMed ID: 24423311
[TBL] [Abstract][Full Text] [Related]
11. Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia.
Christensen MB; Lund A; Calanna S; Jørgensen NR; Holst JJ; Vilsbøll T; Knop FK
J Clin Endocrinol Metab; 2018 Jan; 103(1):288-294. PubMed ID: 29099978
[TBL] [Abstract][Full Text] [Related]
12. The effect of age and glycemic level on the response of the beta-cell to glucose-dependent insulinotropic polypeptide and peripheral tissue sensitivity to endogenously released insulin.
Meneilly GS; Ryan AS; Minaker KL; Elahi D
J Clin Endocrinol Metab; 1998 Aug; 83(8):2925-32. PubMed ID: 9709971
[TBL] [Abstract][Full Text] [Related]
13. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.
Vilsbøll T; Krarup T; Madsbad S; Holst JJ
Regul Pept; 2003 Jul; 114(2-3):115-21. PubMed ID: 12832099
[TBL] [Abstract][Full Text] [Related]
14. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
Nauck MA; Bartels E; Orskov C; Ebert R; Creutzfeldt W
J Clin Endocrinol Metab; 1993 Apr; 76(4):912-7. PubMed ID: 8473405
[TBL] [Abstract][Full Text] [Related]
15. Glucose-dependent insulinotropic polypeptide promotes lipid deposition in subcutaneous adipocytes in obese type 2 diabetes patients: a maladaptive response.
Thondam SK; Daousi C; Wilding JP; Holst JJ; Ameen GI; Yang C; Whitmore C; Mora S; Cuthbertson DJ
Am J Physiol Endocrinol Metab; 2017 Mar; 312(3):E224-E233. PubMed ID: 28073779
[TBL] [Abstract][Full Text] [Related]
16. No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes.
Bergmann NC; Gasbjerg LS; Heimbürger SM; Krogh LSL; Dela F; Hartmann B; Holst JJ; Jessen L; Christensen MB; Vilsbøll T; Lund A; Knop FK
Diabetes Care; 2020 Mar; 43(3):588-596. PubMed ID: 31949084
[TBL] [Abstract][Full Text] [Related]
17. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
[TBL] [Abstract][Full Text] [Related]
18. Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.
Meier JJ; Gallwitz B; Askenas M; Vollmer K; Deacon CF; Holst JJ; Schmidt WE; Nauck MA
Diabetologia; 2005 Sep; 48(9):1872-81. PubMed ID: 16010522
[TBL] [Abstract][Full Text] [Related]
19. Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8.
Nauck M; Schmidt WE; Ebert R; Strietzel J; Cantor P; Hoffmann G; Creutzfeldt W
J Clin Endocrinol Metab; 1989 Sep; 69(3):654-62. PubMed ID: 2668324
[TBL] [Abstract][Full Text] [Related]
20. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.
Elahi D; McAloon-Dyke M; Fukagawa NK; Meneilly GS; Sclater AL; Minaker KL; Habener JF; Andersen DK
Regul Pept; 1994 Apr; 51(1):63-74. PubMed ID: 8036284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
